Amerisource Bergen (ABC) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.

$99.95

Discover Amerisource Bergen’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.

Description

Using our intelligently designed and intuitive dataset, you can quickly understand how Amerisource Bergen (ABC) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Amerisource Bergen (ABC) lobbying for?

Summary of the lobbying data:

Amerisource Bergen hired several lobbying firms to lobby on general issues such as taxation, defense, pharmacy, health issues, and Medicare/Medicaid. They lobbied on specific issues such as advancing emergency preparedness, strengthening national stockpile, medication therapy management, and policies impacting drug pricing and reimbursement. They lobbied government agencies such as the Senate, Executive Office of the President, Department of Health & Human Services, and House of Representatives.

One could infer that Amerisource Bergen is lobbying on these issues to influence legislation and policy decisions that could impact their business operations in the pharmaceutical industry. They may be advocating for policies that benefit their company, such as increased funding for emergency preparedness, stockpiling essential medicines, and Medicare coverage for pharmacist services. They may also be lobbying to prevent policies that could negatively impact their business, such as drug pricing regulations and reductions in Medicare coverage. Overall, the company’s lobbying efforts suggest a focus on maintaining their position in the pharmaceutical industry and influencing government policies to their advantage.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore